
USD
+$0.00
(+0.00%
)At Close (As of Dec 15, 2025)
$149.39B
Market Cap
18.61
P/E Ratio
6.47
EPS
$127.87
52 Week High
$86.17
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $11B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $2.8B |
| Capital Expenditures | $523M |
| Change In Receivables | - |
| Change In Inventory | -$426M |
| Profit Loss | - |
| Cashflow From Investment | -$3.4B |
| Cashflow From Financing | -$3.4B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $3.9B |
| Dividend Payout Common Stock | $3.9B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$1.2B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $480M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Gilead Sciences, Inc. is a premier biopharmaceutical company headquartered in Foster City, California, recognized for its innovative research and development in antiviral therapies, particularly for HIV and hepatitis. Its breakthrough products, including Harvoni and Sovaldi, have revolutionized the treatment landscape for chronic hepatitis C, reflecting the company’s commitment to addressing urgent healthcare challenges. With a robust and expanding therapeutic pipeline, Gilead continues to focus on unmet medical needs, positioning itself as a pivotal force in improving global health outcomes and advancing patient care.